Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities

od Ananthakrishnan, Ashwin N., Donaldson, Tamara, Lasch, Karen, Yajnik, Vijay
Izdano u Inflamm Bowel Dis (2017)

Vedolizumab use in patients with inflammatory bowel diseases undergoing surgery: clinical trials and post-marketing experience

od Shen, Bo, Blake, Aimee, Lasch, Karen, Smyth, Michael, Bhayat, Fatima
Izdano u Gastroenterol Rep (Oxf) (2019)

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies

od Dulai, Parambir S., Osterman, Mark T., Lasch, Karen, Cao, Charlie, Riaz, Faisal, Sandborn, William J.
Izdano u Dig Dis Sci (2019)

Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication

od Guérin, Annie, Mody, Reema, Carter, Valerie, Ayas, Charles, Patel, Haridarshan, Lasch, Karen, Wu, Eric
Izdano u PLoS One (2016)

Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn’s Disease Patients Stratified by Age

od Yajnik, Vijay, Khan, Nabeel, Dubinsky, Marla, Axler, Jeffrey, James, Alexandra, Abhyankar, Brihad, Lasch, Karen
Izdano u Adv Ther (2017)

Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2

od Feagan, Brian G, Schwartz, David, Danese, Silvio, Rubin, David T, Lissoos, Trevor W, Xu, Jing, Lasch, Karen
Izdano u J Crohns Colitis (2018)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation

od Osterman, Mark T., Rosario, Maria, Lasch, Karen, Barocas, Morris, Wilbur, Jayson D., Dirks, Nathanael L., Gastonguay, Marc R.
Izdano u Aliment Pharmacol Ther (2019)

Gastroenterologists’ Perceptions Regarding Ulcerative Colitis and Its Management: Results from a Large-Scale Survey

od Lasch, Karen, Liu, Stephen, Ursos, Lyann, Mody, Reema, King-Concialdi, Kristen, DiBonaventura, Marco, Leberman, Julie, Dubinsky, Marla
Izdano u Adv Ther (2016)

Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis

od Sandborn, William J, Colombel, Jean-Frédéric, Panaccione, Remo, Dulai, Parambir S, Rosario, Maria, Cao, Charlie, Barocas, Morris, Lasch, Karen
Izdano u J Crohns Colitis (2019)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes

od Dulai, Parambir S, Peyrin-Biroulet, Laurent, Demuth, Dirk, Lasch, Karen, Hahn, Kristen A, Lindner, Dirk, Patel, Haridarshan, Jairath, Vipul
Izdano u J Crohns Colitis (2020)

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis

od Scott, Frank I, Luo, Michelle, Shah, Yash, Lasch, Karen, Vajravelu, Ravy K, Mamtani, Ronac, Fennimore, Blair, Gerich, Mark E, Lewis, James D
Izdano u J Crohns Colitis (2020)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

od Bohm, Matthew, Xu, Ronghui, Zhang, Yiran, Varma, Sashidhar, Fischer, Monika, Kochhar, Gursimran, Boland, Brigid, Singh, Siddharth, Hirten, Robert, Ungaro, Ryan, Shmidt, Eugenia, Lasch, Karen, Jairaith, Vipul, Hudesman, David, Chang, Shannon, Lukin, Dana, Swaminath, Arun, Sands, Bruce E., Colombel, Jean‐Frederic, Kane, Sunanda, Loftus, Edward V., Shen, Bo, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Izdano u Aliment Pharmacol Ther (2020)

A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease

od Dulai, Parambir S., Amiot, Aurelien, Peyrin‐Biroulet, Laurent, Jairath, Vipul, Serrero, Melanie, Filippi, Jerome, Singh, Siddharth, Pariente, Benjamin, Loftus, Edward V., Roblin, Xavier, Kane, Sunanda, Buisson, Anthony, Siegel, Corey A., Bouhnik, Yoram, Sandborn, William J., Lasch, Karen, Rosario, Maria, Feagan, Brian G., Bojic, Daniela, Trang‐Poisson, Caroline, Shen, Bo, Altwegg, Romain, Sands, Bruce E., Colombel, Jean‐Frederic, Carbonnel, Franck
Izdano u Aliment Pharmacol Ther (2019)

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

od Shmidt, Eugenia, Kochhar, Gursimran, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Chaudrey, Khadija, Koliani-Pace, Jenna L, Hirten, Robert, Faleck, David, Barocas, Morris, Luo, Michelle, Lasch, Karen, Boland, Brigid S, Singh, Siddharth, Vande Casteele, Niels, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Kane, Sunanda, Loftus, Edward V, Sandborn, William J, Siegel, Corey A, Sands, Bruce E, Colombel, Jean-Frederic, Shen, Bo, Dulai, Parambir S
Izdano u Inflamm Bowel Dis (2018)

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes

od Koliani-Pace, Jenna L, Singh, Siddharth, Luo, Michelle, Hirten, Robert, Aniwan, Satimai, Kochhar, Gursimran, Chang, Shannon, Lukin, Dana, Gao, Youran, Bohm, Matthew, Swaminath, Arun, Gupta, Nitin, Shmidt, Eugenia, Meserve, Joseph, Winters, Adam, Chablaney, Shreya, Faleck, David M, Yang, Jiao, Huang, Zhongwen, Boland, Brigid S, Shashi, Preeti, Weiss, Aaron, Hudesman, David, Varma, Sashidhar, Fischer, Monika, Sultan, Keith, Shen, Bo, Kane, Sunanda, Loftus, Edward V, Sands, Bruce E, Colombel, Jean-Frederic, Sandborn, William J, Lasch, Karen, Siegel, Corey A, Dulai, Parambir S
Izdano u Inflamm Bowel Dis (2019)

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis

od Faleck, David M., Winters, Adam, Chablaney, Shreya, Shashi, Preeti, Meserve, Joseph, Weiss, Aaron, Aniwan, Satimai, Koliani-Pace, Jenna L., Kochhar, Gursimran, Boland, Brigid S., Singh, Siddharth, Hirten, Robert, Shmidt, Eugenia, Kesar, Varun, Lasch, Karen, Luo, Michelle, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Hudesman, David, Chang, Shannon, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Gupta, Nitin, Siegel, Corey A., Shen, Bo, Sandborn, William J., Kane, Sunanda, Loftus, Edward V., Sands, Bruce E., Colombel, Jean-Frederic, Dulai, Parambir S., Ungaro, Ryan
Izdano u Clin Gastroenterol Hepatol (2019)

Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

od Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Dulai, Parambir S.
Izdano u Am J Gastroenterol (2018)

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

od Narula, Neeraj, Peerani, Farhad, Meserve, Joseph, Kochhar, Gursimran, Chaudrey, Khadija, Hartke, Justin, Chilukuri, Prianka, Koliani-Pace, Jenna, Winters, Adam, Katta, Leah, Shmidt, Eugenia, Hirten, Robert, Faleck, David, Parikh, Malav P., Whitehead, Diana, Boland, Brigid S., Singh, Siddharth, Sagi, Sashidhar Varma, Fischer, Monika, Chang, Shannon, Barocas, Morris, Luo, Michelle, Lasch, Karen, Bohm, Matthew, Lukin, Dana, Sultan, Keith, Swaminath, Arun, Hudesman, David, Gupta, Nitin, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Siegel, Corey A., Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Dulai, Parambir S.
Izdano u Am J Gastroenterol (2019)

Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis

od Lukin, Dana, Faleck, David, Xu, Ronghui, Zhang, Yiran, Weiss, Aaron, Aniwan, Satimai, Kadire, Siri, Tran, Gloria, Rahal, Mahmoud, Winters, Adam, Chablaney, Shreya, Koliani-Pace, Jenna L., Meserve, Joseph, Campbell, James P., Kochhar, Gursimran, Bohm, Matthew, Varma, Sashidhar, Fischer, Monika, Boland, Brigid, Singh, Siddharth, Hirten, Robert, Ungaro, Ryan, Lasch, Karen, Shmidt, Eugenia, Jairath, Vipul, Hudesman, David, Chang, Shannon, Swaminath, Arun, Shen, Bo, Kane, Sunanda, Loftus, Edward V., Sands, Bruce E., Colombel, Jean-Frederic, Siegel, Corey A., Sandborn, William J., Dulai, Parambir S.
Izdano u Clin Gastroenterol Hepatol (2020)

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients with Crohn’s Disease

od Dulai, Parambir S., Boland, Brigid S., Singh, Siddharth, Chaudrey, Khadija, Koliani-Pace, Jenna L., Kochhar, Gursimran, Parikh, Malav P., Shmidt, Eugenia, Hartke, Justin, Chilukuri, Prianka, Meserve, Joseph, Whitehead, Diana, Hirten, Robert, Winters, Adam C., Katta, Leah G., Peerani, Farhad, Narula, Neeraj, Sultan, Keith, Swaminath, Arun, Bohm, Matthew, Lukin, Dana, Hudesman, David, Chang, John T., Rivera-Nieves, Jesus, Jairath, Vipul, Zou, GY, Feagan, Brian G., Shen, Bo, Siegel, Corey A., Loftus, Edward V., Kane, Sunanda, Sands, Bruce E., Colombel, Jean-Frederic, Sandborn, William J., Lasch, Karen, Cao, Charlie
Izdano u Gastroenterology (2018)